SCHEMBL3471962

SCHEMBL3471962

CC(C)(O)c1cc(-c2ccc(-c3ccc(C(=O)NC4CC4)c(Cl)c3)s2)n(-c2ccccc2Cl)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 4/20 0.59
NR1H2 P55055 4/20 0.59
NR1H3 Q13133 4/20 0.59
SLC6A12 P48065 1/20 0.40
CNR1 P21554 7/20 0.39
TTK P33981 1/20 0.39
CNR2 P34972 1/20 0.39
HPGD P15428 2/20 0.39
NTRK1 P04629 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CACNB4 O00305 1/20 0.36
CACNA1A O00555 1/20 0.36
CACNA1G O43497 1/20 0.36
CACNG3 O60359 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3473953 0.89 RXRA (0.64) RXRANR1H2NR1H3ALDH1A1MAPT
SCHEMBL3474269 0.86 RXRA (0.61) RXRANR1H2NR1H3CNR1CNR2
SCHEMBL3473338 0.81 RXRA (0.71) RXRANR1H2NR1H3MAPTRAB9A
SCHEMBL3473117 0.80 RXRA (0.64) RXRANR1H2NR1H3
SCHEMBL3473734 0.80 RXRA (0.78) RXRANR1H2NR1H3
SCHEMBL3472543 0.80 RXRA (0.74) RXRANR1H2NR1H3CNR1CNR2
SCHEMBL3471034 0.79 RXRA (0.66) RXRANR1H2NR1H3NTRK1
SCHEMBL3473137 0.79 RXRA (0.71) RXRANR1H2NR1H3HPGDALDH1A1
SCHEMBL3473797 0.79 RXRA (0.71) RXRANR1H2NR1H3
SCHEMBL3472664 0.79 RXRA (0.68) RXRANR1H2NR1H3CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US claimed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.